LENZ Therapeutics (LENZ) Capital Expenditures (2020 - 2026)
LENZ Therapeutics (LENZ) reported Capital Expenditures of $18000.0 for Q1 2026, down 83.64% year-over-year from $110000.0 in Q1 2025, and down 52.63% on a QoQ basis from $38000.0 in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Capital Expenditures data on file, last reported at $18000.0 in Q1 2026.
- Quarterly Capital Expenditures fell 83.64% year-over-year to $18000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $735000.0 (up 134.82% YoY) and the FY2025 annual result came in at $827000.0, up 307.39% from the prior year.
- Capital Expenditures declined to $18000.0 in Q1 2026 per LENZ's latest filing, from $38000.0 in the prior quarter.
- Across five years, Capital Expenditures topped out at $3.3 million in Q1 2022 and bottomed at -$101000.0 in Q3 2024.
- The 5-year median for Capital Expenditures is $152000.0 (2024), against an average of $548000.0.
- The widest annual swing landed in 2022, when Capital Expenditures jumped 809.17%; it then plunged 99.82% in 2023.
- Tracing LENZ's Capital Expenditures over 5 years: stood at $1.0 million in 2022, then plunged by 97.65% to $24000.0 in 2023, then jumped by 612.5% to $171000.0 in 2024, then plunged by 77.78% to $38000.0 in 2025, then plunged by 52.63% to $18000.0 in 2026.
- Per Business Quant, the three latest LENZ Capital Expenditures figures stand at $18000.0 (Q1 2026), $38000.0 (Q4 2025), and $439000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capital Expenditures (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 133.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 230.60 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 21.83 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | 18,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 18,000.00 |
| Mar 31, 2026 | 18,000.00 |
| Dec 31, 2025 | 38,000.00 |
| Dec 31, 2025 | 38,000.00 |
| Sep 30, 2025 | 439,000.00 |
| Sep 30, 2025 | 439,000.00 |
| Jun 30, 2025 | 240,000.00 |
| Jun 30, 2025 | 240,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Mar 31, 2025 | 110,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Dec 31, 2024 | 171,000.00 |
| Sep 30, 2024 | -101,000.00 |
| Sep 30, 2024 | -101,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Jun 30, 2024 | 133,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Jun 30, 2023 | 24,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Mar 31, 2023 | 6,000.00 |
| Dec 31, 2022 | 1.02 Mn |
| Dec 31, 2022 | 1.02 Mn |
| Sep 30, 2022 | 915,000.00 |
| Sep 30, 2022 | 915,000.00 |
| Jun 30, 2022 | 1.39 Mn |
| Jun 30, 2022 | 1.39 Mn |
| Mar 31, 2022 | 3.27 Mn |
| Mar 31, 2022 | 3.27 Mn |
| Dec 31, 2021 | 981,000.00 |
| Dec 31, 2021 | 981,000.00 |
| Sep 30, 2021 | 3.64 Mn |
| Sep 30, 2021 | 3.64 Mn |
| Jun 30, 2021 | 763,000.00 |
| Jun 30, 2021 | 763,000.00 |
| Mar 31, 2021 | 360,000.00 |
| Mar 31, 2021 | 360,000.00 |
| Dec 31, 2020 | 612,000.00 |
| Dec 31, 2020 | 612,000.00 |
| Sep 30, 2020 | 554,000.00 |
| Sep 30, 2020 | 554,000.00 |